287 related articles for article (PubMed ID: 38540775)
1. Immunologic Aspects in Fibrodysplasia Ossificans Progressiva.
Diolintzi A; Pervin MS; Hsiao EC
Biomolecules; 2024 Mar; 14(3):. PubMed ID: 38540775
[TBL] [Abstract][Full Text] [Related]
2. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice.
Lounev V; Groppe JC; Brewer N; Wentworth KL; Smith V; Xu M; Schomburg L; Bhargava P; Al Mukaddam M; Hsiao EC; Shore EM; Pignolo RJ; Kaplan FS
J Bone Miner Res; 2024 May; 39(4):382-398. PubMed ID: 38477818
[TBL] [Abstract][Full Text] [Related]
4. Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification.
Matsuo K; Chavez RD; Barruet E; Hsiao EC
Curr Osteoporos Rep; 2019 Dec; 17(6):387-394. PubMed ID: 31721068
[TBL] [Abstract][Full Text] [Related]
5. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
Alessi Wolken DM; Idone V; Hatsell SJ; Yu PB; Economides AN
Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737
[TBL] [Abstract][Full Text] [Related]
6. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.
Barruet E; Morales BM; Lwin W; White MP; Theodoris CV; Kim H; Urrutia A; Wong SA; Srivastava D; Hsiao EC
Stem Cell Res Ther; 2016 Aug; 7(1):115. PubMed ID: 27530160
[TBL] [Abstract][Full Text] [Related]
7. Elevated plasma RANTES in fibrodysplasia ossificans progressiva - A novel therapeutic target?
Grgurević L; Novak R; Trkulja V; Hamzić LF; Hrkač S; Grazio S; Santini M
Med Hypotheses; 2019 Oct; 131():109313. PubMed ID: 31443758
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification.
Yamamoto M; Stoessel SJ; Yamamoto S; Goldhamer DJ
J Bone Miner Res; 2022 Nov; 37(11):2077-2093. PubMed ID: 35637634
[TBL] [Abstract][Full Text] [Related]
9. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.
Culbert AL; Chakkalakal SA; Theosmy EG; Brennan TA; Kaplan FS; Shore EM
Stem Cells; 2014 May; 32(5):1289-300. PubMed ID: 24449086
[TBL] [Abstract][Full Text] [Related]
10. Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.
Kaplan FS; Zeitlin L; Dunn SP; Benor S; Hagin D; Al Mukaddam M; Pignolo RJ
Bone; 2018 Apr; 109():281-284. PubMed ID: 29241828
[TBL] [Abstract][Full Text] [Related]
11. An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.
Hino K; Zhao C; Horigome K; Nishio M; Okanishi Y; Nagata S; Komura S; Yamada Y; Toguchida J; Ohta A; Ikeya M
Stem Cell Reports; 2018 Nov; 11(5):1106-1119. PubMed ID: 30392977
[TBL] [Abstract][Full Text] [Related]
12. Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP).
Wang H; Shore EM; Pignolo RJ; Kaplan FS
Bone; 2018 Apr; 109():218-224. PubMed ID: 29170109
[TBL] [Abstract][Full Text] [Related]
13. Recent progress in drug development for fibrodysplasia ossificans progressiva.
Meng X; Wang H; Hao J
Mol Cell Biochem; 2022 Oct; 477(10):2327-2334. PubMed ID: 35536530
[TBL] [Abstract][Full Text] [Related]
14. The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator.
Lin H; Shi F; Gao J; Hua P
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31341010
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic stem-cell contribution to ectopic skeletogenesis.
Kaplan FS; Glaser DL; Shore EM; Pignolo RJ; Xu M; Zhang Y; Senitzer D; Forman SJ; Emerson SG
J Bone Joint Surg Am; 2007 Feb; 89(2):347-57. PubMed ID: 17272450
[TBL] [Abstract][Full Text] [Related]
16. iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.
Gao P; Inada Y; Hotta A; Sakurai H; Ikeya M
Stem Cell Res Ther; 2024 Mar; 15(1):83. PubMed ID: 38500216
[TBL] [Abstract][Full Text] [Related]
17. BMP-dependent, injury-induced stem cell niche as a mechanism of heterotopic ossification.
Kan C; Ding N; Yang J; Tan Z; McGuire TL; Lu H; Zhang K; Berger DMP; Kessler JA; Kan L
Stem Cell Res Ther; 2019 Jan; 10(1):14. PubMed ID: 30635039
[TBL] [Abstract][Full Text] [Related]
18. [Fibrodysplasia ossificans progressiva and osteoimmunology].
Katagiri T
Clin Calcium; 2016 May; 26(5):691-8. PubMed ID: 27117614
[TBL] [Abstract][Full Text] [Related]
19. Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1.
Aykul S; Huang L; Wang L; Das NM; Reisman S; Ray Y; Zhang Q; Rothman N; Nannuru KC; Kamat V; Brydges S; Troncone L; Johnsen L; Yu PB; Fazio S; Lees-Shepard J; Schutz K; Murphy AJ; Economides AN; Idone V; Hatsell SJ
J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35511419
[TBL] [Abstract][Full Text] [Related]
20. Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report.
Singh S; Kidane J; Wentworth KL; Motamedi D; Morshed S; Schober AE; Hsiao EC
BMC Musculoskelet Disord; 2020 Apr; 21(1):204. PubMed ID: 32245464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
